<DOC>
	<DOC>NCT02974855</DOC>
	<brief_summary>This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.</brief_summary>
	<brief_title>PF-06741086 Multiple Dose Study in Severe Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Severe hemophilia A or B (Factor VIII or Factor IX activity â‰¤ 1%) with no known Factor VIII or Factor IX inhibitors Episodic (ondemand) treatment regimen prior to screening At least 6 acute bleeding episodes during the 6month period prior to screening Known coronary artery, thrombotic, or ischemic disease Detectable or documented history of inhibitors against Factor VIII or Factor IX during the 12month period prior to screening Concomitant treatment with rFVIIa or activated prothrombin complex concentrate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hemophilia</keyword>
</DOC>